# BCG-unresponsive

Source: https://onco.cc/terms/bcg-unresponsive/  
OnCo record `bcg-unresponsive` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The FDA's definition of early bladder cancer that has failed adequate BCG treatment, the population in which most new bladder drugs are first approved.

## Summary

Persistent or recurrent CIS within 12 months of adequate BCG (at least 5 of 6 induction and 2 of 3 maintenance doses), or high-grade Ta/T1 recurrence within 6 months, or T1 high-grade at first evaluation after induction. Historically treated with radical cystectomy; now pembrolizumab, nadofaragene, N-803 + BCG, TAR-200, and (filing) cretostimogene offer bladder-sparing options with CR rates of 40-80%.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- EAU guidelines: non-muscle-invasive bladder cancer: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cretostimogene grenadenorepvec](https://onco.cc/drugs/cretostimogene/), [Gemcitabine intravesical system (TAR-200)](https://onco.cc/drugs/tar-200/), [Intravesical BCG](https://onco.cc/drugs/bcg-intravesical/), [Nadofaragene firadenovec](https://onco.cc/drugs/nadofaragene-firadenovec/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- trials: [BOND-003](https://onco.cc/trials/bond-003/), [QUILT 3.032](https://onco.cc/trials/quilt-3-032/), [SunRISe-1](https://onco.cc/trials/sunrise-1/)
- technologies: [Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)](https://onco.cc/technologies/bcg-and-intravesical-therapy/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/)
- pathways: [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/)

---
JSON: https://onco.cc/api/v1/entities/bcg-unresponsive.json